Nyrada Inc.

NYR

AU0000070195

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 07:10:51 20/05/2024 BST			5-day change	1st Jan Change
0.068 ^AUD	+4.62%		-5.56%	+209.09%

04-30	Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	MT
04-18	Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024

Nyrada Inc. Announces Appointment of Ruediger Weseloh as Director

January 15, 2020 at 10:26 pm

Nyrada Inc. announced the appointment of Ruediger Weseloh as Director. Date of appointment is 4 June 2019.

Latest news about Nyrada Inc.

Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	04-30	MT
Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024	04-18
Transcript : Nyrada Inc. - Special Call	04-10
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program	04-10	MT
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	03-28	MT
Nyrada Raises AU$1.8 Million via Placement	03-06	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2023	02-20	CI
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%	12-08	MT
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23	CI
Australian Shares Flat as June Unemployment Rate Remains at 3.5%	20/07/23	MT
Nyrada Halves Director Fees; Shares Jump 37%	20/07/23	MT
Nyrada Opts to Advance NYR-BI03 Brain Injury Drug Candidate	12/06/23	MT
Nyrada Completes Preclinical Studies on Cholesterol Lowering Medication	26/05/23	MT
Nyrada Completes Preclinical Dose Formulation for Cholesterol Lowering Medication	11/04/23	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	23/02/23	CI
Nyrada Extends R&D Deal for Brain Injury Drug Candidate	18/01/23	MT
Nyrada Inc. Announces Collaboration with Walter Reed and UNSW Extended to 2025	17/01/23	CI
Nyrada Advances Preclinical Studies for Brain Injury Drug Candidate	11/01/23	MT
Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program	10/01/23	CI
Nyrada Receives $804,600 R&D Tax Refund; Shares fall 11%	18/11/22	MT
Nyrada Inc. Announces Efficacy Study Published in Journal of Lipid Research	09/10/22	CI
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	29/08/22	CI
Nyrada Inc. Announces Board Changes	01/08/22	CI
Nyrada Validates Effectivity of Inhibitor Drug to Block Early Atherosclerosis; Shares Fall 6%	20/07/22	MT
Nyrada Delays Phase 1 Cholesterol Trial Due to Lockdown in China; Shares Fall 7%	29/06/22	MT

Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Companyâs two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.

Sector

Pharmaceuticals

Calendar

25/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NYRADA INC.	+209.09%	7.8M
ELI LILLY AND COMPANY	+34.35%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-3.49%	372B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	294B
ASTRAZENECA PLC	+14.11%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+9.21%	168B